论文部分内容阅读
目的探讨EB病毒(Epstein-Barr virus,EBV)感染与乳腺浸润性导管癌发生发展的相关性及其与癌基因c-erbB-2表达的相关性。方法应用免疫组化法(immunohistochemmistry,IHC)检测乳腺浸润性导管癌组织、相应癌旁组织及乳腺良性增生组织石蜡标本中EB病毒核蛋白-1(EBNA-1)的表达状况,随后应用相同方法分别检测EBNA-1阳性及阴性石蜡标本癌基因c-erbB-2的表达状况。结果 80例乳腺浸润性导管癌组织中有24例EBNA-1阳性(28.75%),相应癌旁组织及乳腺良性增生组织均为阴性,EBNA-1检出率的差别有统计学意义(χ2=28.235,P<0.001;χ2=6.336,P=0.012)。EBNA-1阳性和EBNA-1阴性乳腺癌在年龄、组织病理学分级、临床分期、淋巴结转移的差异均无统计学意义(P值分别为0.868、0.915、0.748、0.812)。在24例EBNA-1阳性乳腺癌标本中,均有人类表皮生长因子受体-2(c-erbB-2)表达,阳性率为100%;而在56例EBNA-1阴性乳腺癌标本中仅有25例表达,阳性率为44.6%,二者差异有统计学意义(P<0.01)。结论 EB病毒感染对部分乳腺浸润性导管癌的发生发展可能有影响,且可能上调患者癌基因c-erbB-2的表达,但与患者的年龄、组织病理学分级、临床分期和淋巴结转移无关。
Objective To investigate the correlation between the Epstein-Barr virus (EBV) infection and the occurrence and development of breast invasive ductal carcinoma and its correlation with the expression of oncogene c-erbB-2. Methods The expression of Epstein-Barr virus nucleoprotein-1 (EBNA-1) in invasive ductal carcinoma tissues, adjacent paracancerous tissues and benign breast hyperplasia tissues was detected by immunohistochemical method (IHC). Subsequently, the same method The expression of c-erbB-2 in EBNA-1positive andnegative paraffin-embedded specimens was detected. Results The positive rate of EBNA-1 in 80 cases of invasive ductal carcinomas of the breast was 24 cases (28.75%), corresponding paracancerous tissues and benign breast hyperplasia tissues, the difference was statistically significant (χ2 = 28.235, P <0.001; χ2 = 6.336, P = 0.012). EBNA-1 positive and EBNA-1 negative breast cancer in age, histopathological grading, clinical stage, lymph node metastasis were no significant difference (P values were 0.868,0.915,0.748,0.812). The positive rate of human epidermal growth factor receptor-2 (c-erbB-2) expression was 100% in 24 EBNA-1 positive breast cancer specimens, while only 56 of EBNA-1 negative breast cancer specimens 25 cases were expressed, the positive rate was 44.6%, the difference was statistically significant (P <0.01). Conclusion Epstein-Barr virus (EBV) infection may affect the occurrence and development of some breast invasive ductal carcinomas and may up-regulate the expression of c-erbB-2, but not with the age, histopathological grade, clinical stage and lymph node metastasis.